Kevin Brady Sells 3,400 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CFO Kevin Brady sold 3,400 shares of the company’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $625.24, for a total transaction of $2,125,816.00. Following the completion of the sale, the chief financial officer directly owned 12,830 shares in the company, valued at approximately $8,021,829.20. The trade was a 20.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Medpace Stock Performance

Shares of Medpace stock traded down $0.72 on Monday, hitting $620.03. The company’s stock had a trading volume of 171,851 shares, compared to its average volume of 346,791. The company has a market capitalization of $17.31 billion, a price-to-earnings ratio of 36.34, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15. The firm has a fifty day moving average price of $550.16 and a 200-day moving average price of $492.03. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter in the previous year, the company earned $3.10 earnings per share. The company’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Royal Bank Of Canada lifted their target price on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Mizuho upped their price target on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and boosted their price objective for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, Medpace currently has a consensus rating of “Hold” and a consensus price target of $584.18.

Hedge Funds Weigh In On Medpace

Several hedge funds have recently bought and sold shares of MEDP. California State Teachers Retirement System raised its holdings in Medpace by 53,619.6% during the second quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company’s stock worth $7,408,778,000 after purchasing an additional 13,963,607 shares during the last quarter. HB Wealth Management LLC grew its holdings in Medpace by 3.9% in the second quarter. HB Wealth Management LLC now owns 1,858 shares of the company’s stock valued at $984,000 after purchasing an additional 69 shares during the last quarter. AlphaGrep UK Ltd purchased a new position in shares of Medpace in the second quarter valued at $466,000. TD Waterhouse Canada Inc. increased its position in shares of Medpace by 1,120.0% in the second quarter. TD Waterhouse Canada Inc. now owns 122 shares of the company’s stock valued at $66,000 after buying an additional 112 shares in the last quarter. Finally, Nykredit A S acquired a new position in shares of Medpace during the 2nd quarter worth $356,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.